3D bioprinting is a relatively new specialty used in the field of tissue engineering for combining cells, biomaterials, and growth factors to manufacture tissue-like structures/organs to assist in research and in reconstructive/regenerative surgeries for the rebuilding of damaged organs.  Current 3D bioprinting techniques are high cost, limited in their ability to accurately place biomaterial in hard to reach areas due to their use of shorter needles, and the design of their dispensing system makes it difficult to use them in handheld pens limiting their utility to stationary bioprinters.

The conceptual technology presents a novel handheld 3D printer utilizing a mixing pen where the nozzle provides precise control over the biomaterial dispensing operation and real-time mixing of material during the extrusion period resulting in minimal material waste.  The pen’s handle allows easy to control dispensing of the material by the practitioner.  The technology can be operated by robotics or actuators/motors providing added precision during surgeries.

Competitive Advantages

• The new 3D bioprinting pen allows for real-time mixing of materials using multiple syringes minimizing waste and reducing costs rather than the premixing of material used in current 3D single needle devices.
• Current 3D systems using shorter needles and stationary printers require physical handling/placement of biomaterial on the patient increasing risk of infection.   The Rowan technology eliminates these concerns by use of a long, multiaxial needle in a handheld pen applicator.

Opportunity

• The global 3D printing healthcare market was valued at $973 million in 2018 and is projected to grow at a CAGR of 18.2% through 2026, reaching a value of $3.7 billion.
• 3D printing provides advantages over traditional reconstructive surgeries by reducing patient risk and decreasing the duration of hospital stays. 

Rowan University is seeking a partner(s) for further development and commercialization of this technology. The inventor is available to collaborate with interested companies.